Ontology highlight
ABSTRACT: Background
HSG4112 is a clinical-stage drug candidate for the treatment of obesity. Here, we report its discovery and preclinical efficacy.Methods
In high-fat diet (HFD)-induced obese male C57BL/6J mice, we tested the weight loss effect of synthetic compounds derived from a structure-activity relationship (SAR) study of glabridin, a natural compound known to reduce body weight and influence energy homeostasis. After selecting HSG4112 as our optimized compound from this discovery method, we characterized its pharmacological effects on parameters related to obesity through in vivo metabolic and biochemical measurements, histology and gene expression analysis, and indirect calorimetry.Results
Through the SAR study, we identified four novel components of glabridin perti
SUBMITTER: Choi LS
PROVIDER: S-EPMC7752758 | biostudies-literature | 2021 Jan
REPOSITORIES: biostudies-literature